S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails success in blocking Iran's unprecedented attack. G7 democracies condemn attack
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails success in blocking Iran's unprecedented attack. G7 democracies condemn attack
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails success in blocking Iran's unprecedented attack. G7 democracies condemn attack
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails success in blocking Iran's unprecedented attack. G7 democracies condemn attack
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
NASDAQ:SAVAW

Cassava Sciences (SAVAW) Stock Price, News & Analysis

$5.06
-1.52 (-23.10%)
(As of 04/12/2024 ET)
Today's Range
$5.00
$6.95
50-Day Range
$3.68
$7.98
52-Week Range
$2.60
$11.02
Volume
267,392 shs
Average Volume
371,227 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

SAVAW Stock Price History

SAVAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive SAVAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SAVAW
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
No Data
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Remi Barbier (Age 64)
    Founder, Chairman, President & CEO
    Comp: $1.2M
  • Mr. Eric J. Schoen (Age 56)
    Chief Financial Officer
    Comp: $460k
  • Mr. R. Christopher Cook (Age 60)
    Senior VP, Company Secretary & General Counsel
    Comp: $425k
  • Dr. James W. Kupiec M.D. (Age 71)
    Chief Medical Officer
    Comp: $435k
  • Dr. George Thornton Ph.D.
    Senior Vice President of Technology
  • Mr. Michael Zamloot
    Senior Vice President of Technical Operations
  • Dr. Michael Marsman Pharm.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D.
    Senior Vice President of Neuroscience

SAVAW Stock Analysis - Frequently Asked Questions

How have SAVAW shares performed in 2024?

Cassava Sciences' stock was trading at $7.01 at the beginning of the year. Since then, SAVAW stock has decreased by 27.8% and is now trading at $5.06.
View the best growth stocks for 2024 here
.

How do I buy shares of Cassava Sciences?

Shares of SAVAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAVAW) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners